MXiPr, also known as Methoxisopropamine, Isopropyloxetamine, and Isopropyxetamine, is a recreational designer drug celebrated for its dissociative effects. It falls under the arylcyclohexylamine derivative category, sharing kinship with well-known substances like ketamine and methoxetamine. This compound was initially detected in Slovenia in December 2020 and became subject to legal restrictions, being prohibited in Hungary in April 2021.
1. What is Methoxisopropamine (MXiPr)?
Methoxisopropamine, often referred to as MXiPr, is a recreational designer drug recognized for its dissociative effects. It belongs to the arylcyclohexylamine derivative class, sharing similarities with substances like ketamine and methoxetamine.
2. What are the common names for Methoxisopropamine?
MXiPr may also be known as Methoxisopropamine, Isopropyloxetamine, and Isopropyxetamine.
3. How is Methoxisopropamine used?
Methoxisopropamine is typically consumed orally, but it may also be used through other methods. It is often available in various forms, including powder or crystalline form. Keep in mind that the use of MXiPr carries potential health risks and legal implications in many regions.
4. Is Methoxisopropamine legal?
The legal status of Methoxisopropamine can differ significantly depending on your country or jurisdiction. In some places, it may be classified as a controlled or illegal substance, while in others, it may be unregulated or reserved for research purposes. It’s crucial to be aware of the specific regulations in your area.
5. What are the effects of Methoxisopropamine?
Methoxisopropamine’s effects are similar to those of other dissociative drugs. Users may experience altered perception, hallucinations, a sense of disconnection from reality, and changes in sensory experiences. The intensity and duration of these effects can vary from person to person.
6. What are the potential risks and side effects of using Methoxisopropamine?
The use of Methoxisopropamine can lead to various adverse effects, including disorientation, confusion, nausea, anxiety, and potential risks to physical and mental health. Long-term use may result in adverse health outcomes, such as kidney and bladder issues.
7. Can Methoxisopropamine be addictive?
The addictive potential of Methoxisopropamine is not well-studied, but like other dissociative substances, it may carry the risk of psychological dependence, especially with frequent or heavy use.
8. Is it safe to use Methoxisopropamine?
Safety concerns surround the use of Methoxisopropamine due to limited research and potential adverse effects. Using MXiPr can be risky, and its safety is not guaranteed, mainly when obtained from unregulated sources.
9. Can Methoxisopropamine be detected in drug tests?
Methoxisopropamine is not typically included in standard drug tests. However, specialized testing may be capable of detecting its presence. It’s essential to be aware of the testing methods used in your specific situation.
10. What should I do if I or someone I know is experiencing adverse effects from Methoxisopropamine use?
If you or someone you know is experiencing adverse effects or health concerns related to Methoxisopropamine use, seek immediate medical attention. Be honest with healthcare professionals about substance use to ensure proper care and treatment.
11. Where can I find reliable information about Methoxisopropamine?
For accurate and up-to-date information on Methoxisopropamine, consult trusted sources such as government health agencies, substance abuse prevention organizations, and medical professionals. Always exercise caution and prioritize your safety when researching and considering the use of substances like MXiPr.
- “Analytical Report for MXiPr” (PDF). Conducted by the National Forensic Laboratory under the jurisdiction of the Police, Ministry of the Interior, Republic of Slovenia. This report delves into the chemical composition of MXiPr and is essential in understanding its properties. The chemical formula is described as “2‐(3‐methoxyphenyl)‐2‐[(propan‐2‐yl)amino]cyclohexan‐1‐one C16H23NO2.”
- “Amendment of Decree No 55/2014 of 30 December 2014 on substances or groups of compounds classified as new psychoactive substances.” Issued by the Minister for Human Capacities under the Government of Hungary. This amendment, identified as 2021/225/HU, pertains to the legal status and regulation of substances like MXiPr, reflecting the evolving policies and restrictions.